DUB and Ubiquitin Enzyme Activity Assays

Activity-Based DUB and Ubiquitin Enzyme Assays for Targeted Protein Degradation and Drug Discovery

The ubiquitin system — comprising the hierarchical E1→E2→E3 ubiquitination cascade that installs ubiquitin on substrate proteins, and the ~100 deubiquitinating enzymes (DUBs) that remove ubiquitin to reverse or edit the ubiquitin signal — regulates nearly every aspect of eukaryotic cell biology, including protein stability, proteasomal degradation, DNA damage repair, NF-κB signaling, endocytic trafficking, autophagy, and innate immune responses. Dysregulation of ubiquitin enzymes is implicated in a broad spectrum of diseases: DUB overexpression or mutation drives oncogenesis (USP7 in multiple myeloma, USP14 in ovarian cancer, USP28 in colorectal cancer), E3 ligase dysfunction underlies neurodegenerative disorders (Parkin/PINK1 in Parkinson's disease, UBE3A in Angelman syndrome), and aberrant ubiquitin signaling contributes to inflammatory and autoimmune conditions (A20/TNFAIP3 in rheumatoid arthritis, NOD2 ubiquitination in Crohn's disease). The emergence of targeted protein degradation — particularly PROTACs (PROteolysis TArgeting Chimeras) that recruit E3 ligases to ubiquitinate and degrade disease-relevant proteins — has elevated the ubiquitin enzyme system from a therapeutic target class to a central enabling technology for pharmacological intervention across the proteome.

Activity-based DUB and ubiquitin enzyme assays differ fundamentally from abundance-based methods (western blot, immunofluorescence, RNA-seq) in that they measure the functional catalytic activity of the enzyme — not its presence or quantity. This distinction is critical because DUBs and E3 ligases are frequently regulated not at the expression level but through post-translational modifications (phosphorylation, ubiquitination itself), protein-protein interactions (adaptor proteins, substrate binding), and conformational changes that modulate activity independently of protein abundance. Activity-based probes (ABPs) — suicide inhibitors that form a covalent bond with the active-site cysteine of DUBs (or the catalytic cysteine of certain E3 ligases) and are equipped with detection tags (biotin, fluorophores, TMT) — capture the functional state of the enzyme at the time of probe treatment, providing a direct readout of catalytic activity that is orthogonal to and more mechanistically informative than abundance-based measurements. Our service integrates these activity-based approaches with complementary antibody-based and MS-based ubiquitination analysis platforms to deliver a complete picture of ubiquitin enzyme function in any biological context. For comprehensive ubiquitination site mapping, our Ubiquitylomics Analysis service provides global K-ε-GG ubiquitin remnant profiling by LC-MS/MS.

Find Your Solution: Research Goal → DUB and Ubiquitin Enzyme Activity Assay Strategy

Integrated Assay Platforms for DUB and Ubiquitin Enzyme Activity Profiling

Our DUB and ubiquitin enzyme activity assay service portfolio encompasses four complementary platforms — biochemical activity assays, E1/E2/E3 cascade reconstitution, cell-based activity probes, and ubiquitin remnant proteomics — each optimized for specific stages of the drug discovery pipeline from target identification and validation through hit identification, lead optimization, and preclinical candidate characterization. Platform selection depends on the enzyme target (DUB vs. E3 ligase vs. full cascade), throughput requirements, desired mechanistic information, and the biological context of the study.

Biochemical DUB Activity Assays — Fluorogenic and MS-Based Readout Platforms

For direct, quantitative measurement of DUB catalytic activity in purified enzyme systems, we offer a comprehensive suite of biochemical activity assays using ubiquitin-based substrates with fluorogenic, chemiluminescent, and mass spectrometry readout formats. The Ub-AMC (ubiquitin-7-amido-4-methylcoumarin) assay represents the most widely used biochemical DUB activity format: upon DUB-catalyzed hydrolysis of the C-terminal amide bond between ubiquitin Gly76 and AMC, the free AMC fluorophore emits fluorescence at 460 nm (excitation 380 nm), providing a continuous real-time readout of DUB activity that is compatible with high-throughput screening (384-well and 1536-well plate formats, Z′ > 0.7 for optimized assays). For DUBs that show poor activity against Ub-AMC, alternative fluorogenic substrates including Ub-PL (ubiquitin-phospholipase A₂ substrate, which generates a larger fluorescence increase upon cleavage due to relief of self-quenching) and FRET-based diubiquitin probes (donor-acceptor fluorophore pair flanking the isopeptide bond, providing linkage-specific DUB activity readout) are available. For non-fluorogenic readout, activity-based probes (ABPs) — including biotin-Ub-VME (vinyl methyl ester) and biotin-Ub-PA (propargyl amide) — form an irreversible covalent bond with the DUB active-site cysteine, enabling pull-down and LC-MS/MS-based identification and quantification of active DUBs. All biochemical assays include appropriate positive controls (recombinant USP2 catalytic domain, 1–10 nM), negative controls (N-ethylmaleimide-treated DUB, 10 mM), and DUB inhibitor controls (PR-619, 10 μM) for assay validation.

E1/E2/E3 Ubiquitination Cascade Assays — Reconstituted Systems for Ligase Activity Assessment

For assessing E3 ligase activity — a critical requirement for PROTAC degrader development where the hijacked E3 ligase must retain catalytic competence to ubiquitinate the target-PROTAC-E3 ternary complex — we offer fully reconstituted E1/E2/E3 ubiquitination cascade assays. The complete cascade is assembled with purified recombinant components: E1 activating enzyme (UBA1 or UBA6, 50–100 nM), cognate E2 conjugating enzyme (selected from a panel of ~40 E2 enzymes, 0.5–2 μM), E3 ligase of interest (10–500 nM, purified catalytic domain or full-length FLAG-tagged), ubiquitin (10–50 μM, ±biotin or FLAG tag for detection), and ATP (2 mM) in an optimized buffer system (50 mM Tris pH 7.5, 5 mM MgCl₂, 1 mM DTT). Autoubiquitination activity (the E3 ligase ubiquitinating itself, measured by anti-ubiquitin immunoblot or streptavidin-HRP detection of biotin-ubiquitin incorporation into the E3) serves as a first-line activity readout. Substrate-specific ubiquitination assays — where a specific substrate protein (e.g., p53 for MDM2, HIF-1α for VHL, NRF2 for KEAP1, IκBα for SCF-β-TrCP) is added to the cascade — provide target-relevant ubiquitination activity measurement. For PROTAC ternary complex-induced ubiquitination, the PROTAC compound, target protein, and E3 ligase are co-incubated in the cascade to measure compound-dependent ubiquitination with PROTAC concentration-response curves (1 nM–10 μM, 6-point or 10-point titration). For detailed analysis of ubiquitination site specificity, our Ubiquitylomics Analysis service provides LC-MS/MS-based mapping of ubiquitinated lysine residues.

Cell-Based DUB Target Engagement and Proteome-Wide Selectivity Profiling

For assessing DUB target engagement in physiologically relevant cellular environments — a critical translational step that bridges biochemical potency and cellular efficacy — we offer cell-based DUB activity profiling using cell-permeable activity-based probes (ABPs). The cell-permeable ubiquitin-PA probe (typically conjugated with a poly-arginine (cR10) cell-penetrating peptide sequence) enters live cells and covalently labels active DUBs in their native cellular context, capturing the endogenous activity state of each DUB as modulated by cellular signaling, protein-protein interactions, and pharmacological intervention. Following probe treatment (1–10 μM, 1–4 hours, 37°C), cells are lysed, probe-labeled DUBs are captured by streptavidin pull-down, and identified/quantified by label-free or TMT-LC-MS/MS. Target occupancy — the percentage of a DUB's active sites that are occupied by a pre-administered inhibitor and thus unavailable for probe labeling — is calculated as the ratio of probe-labeled DUB signal in inhibitor-treated vs. vehicle-treated cells, providing a quantitative, activity-based measure of cellular target engagement that directly informs the pharmacokinetic-pharmacodynamic (PK-PD) relationship. Proteome-wide selectivity profiling by competitive ABPP compares the probe-labeling signal across all detectable DUBs between inhibitor-treated and untreated samples, enabling unbiased assessment of selectivity against the entire DUB family — a critical requirement for avoiding off-target toxicity in DUB-targeted drug development programs.

Ubiquitin Remnant (K-ε-GG) LC-MS/MS Proteomics for Global Ubiquitination Analysis

While activity-based assays directly measure DUB and E3 enzyme function, ubiquitin remnant proteomics provides a complementary global view of the downstream consequences of ubiquitin enzyme activity — the ubiquitination state of the proteome. Upon trypsin digestion of cellular proteins, ubiquitinated lysine residues retain a di-glycine remnant (K-ε-GG, +114.043 Da) on the formerly modified lysine, which serves as a stable mass spectrometry signature for site-level ubiquitination quantification. Our K-ε-GG ubiquitin remnant proteomics workflow uses anti-K-ε-GG antibody (PTMScan) enrichment from tryptic digests (2–5 mg total protein per IP), TMT-11-plex labeling for multiplexed quantification, and nanoLC-MS/MS on Orbitrap Fusion Lumos or Q Exactive HF-X platforms with MaxQuant or Proteome Discoverer databases searching, ubiquitination site localization (Andromeda score > 40, localization probability > 0.75), and differential ubiquitination analysis between experimental conditions. This platform identifies and quantifies 8,000–20,000 unique ubiquitination sites per experiment, providing a comprehensive view of ubiquitin signaling changes induced by DUB inhibition, E3 ligase modulation, or PROTAC-mediated degradation — enabling researchers to connect changes in ubiquitin enzyme activity directly to the proteome-wide ubiquitination response.

Why Choose Our DUB and Ubiquitin Enzyme Activity Assay Service

Workflow: From Research Question to Activity-Based Ubiquitin Enzyme Insights

Applications in DUB and Ubiquitin Enzyme Activity Assay Research

Activity-based DUB and ubiquitin enzyme assays have become indispensable tools in drug discovery and basic research, providing functional readouts of enzyme activity that inform target identification, hit validation, lead optimization, and mechanistic understanding across oncology, neurodegeneration, inflammation, and targeted protein degradation. The following application areas represent the most active use cases for our assay platforms.

Case Study: Neutron-Encoded Diubiquitins to Profile Linkage Selectivity of Deubiquitinating Enzymes by Multiplexed Intact Mass Spectrometry

In a 2023 study published in Nature Communications (CC BY 4.0), van Tol et al. developed a groundbreaking mass spectrometry-based platform for multiplexed profiling of DUB linkage selectivity, using neutron-encoded (¹³C/¹⁵N) diubiquitin probes that enable simultaneous detection of DUB activity across all eight ubiquitin chain linkage types from a single LC-MS experiment — a methodological advance that transforms our ability to characterize DUB specificity, substrate preference, and inhibitor selectivity in a single, unified assay.

Background: Deubiquitinating enzymes exhibit differential selectivity for the eight ubiquitin chain linkage types (Met1/M1-linear, K6, K11, K27, K29, K33, K48, K63), and this linkage selectivity is a critical determinant of DUB biological function. K48-linked ubiquitin chains target substrates for proteasomal degradation, K63-linked chains regulate signaling complex assembly and kinase activation, Met1-linked linear chains activate NF-κB signaling, and K11/K29/K33 linkages are associated with endoplasmic reticulum-associated degradation and lysosomal trafficking. Traditional methods for assessing DUB linkage selectivity required separate enzymatic reactions for each linkage type, using individual diubiquitin substrates in parallel wells, and comparing cleavage rates across assays — a labor-intensive, reagent-intensive approach that introduced inter-assay variability and prevented direct competitive comparison of linkage preferences within a single reaction. The authors addressed this gap by creating a multiplexed system in which all eight diubiquitin probes can be simultaneously incubated with a single DUB enzyme and the cleavage products are distinguished by intact protein mass spectrometry without any separation step.

Approach: The authors synthesized all eight native diubiquitin linkage types — M1-linear (through the N-terminal methionine), K6, K11, K27, K29, K33, K48, and K63 — using established enzymatic and chemical methods. Each diubiquitin was encoded with a distinct molecular mass by incorporating neutron-encoded amino acids (¹³C₆-arginine, ¹³C₆-lysine, ¹⁵N₂-lysine, or ²H₁₀-leucine) at defined positions, generating a mass difference of 6–10 Da between any two probes. All eight mass-encoded diubiquitins were pooled and incubated with a single DUB enzyme in a single reaction; at defined time points, aliquots were analyzed by intact protein LC-MS on a QTOF or Orbitrap instrument, and the relative abundance of each diubiquitin substrate and its corresponding monoubiquitin cleavage product was deconvoluted by mass difference. This experimental design was applied to profile 22 human DUBs spanning the USP (USP2, USP4, USP7, USP8, USP9x, USP10, USP16, USP21, USP30), OTU (OTUB1, OTUB2, OTUD1, OTUD2, OTUD3, OTULIN, Cezanne/OTUD7B), UCH (UCHL1, UCHL3, UCHL5), and MJD (ATXN3, ATXN3L, JOSD1) subfamilies, generating comprehensive three-dimensional activity landscapes (linkage selectivity × time × enzyme concentration) for each DUB.

Key Findings:

• Multiplexed DUB linkage selectivity profiling by intact protein MS: The neutron-encoded diubiquitin strategy achieved simultaneous, unambiguous detection of cleavage activity across all eight ubiquitin linkage types from a single LC-MS injection, with the 6–10 Da mass differences between probes providing confident assignment of each diubiquitin and monoubiquitin species without the need for chromatographic separation of the individual diubiquitin linkage types — a transformative simplification that reduces sample requirements and eliminates inter-assay variability inherent in parallel single-substrate experiments
• Linkage selectivity is concentration-dependent for promiscuous DUBs: A key biological finding was that USP-family DUBs — traditionally described as linkage-promiscuous — display pronounced linkage selectivity when assayed at low enzyme concentrations (0.1–1 nM), with selectivity narrowing at higher concentrations (10–100 nM). This reveals that the apparent promiscuity of many USPs is at least partially a consequence of supra-physiological enzyme concentrations used in standard biochemical assays, and that substrate competition at physiologically relevant concentrations reveals previously unrecognized selectivity preferences — a finding with direct implications for therapeutic DUB target selection and inhibitor development, as the degree of selectivity determines whether a DUB inhibitor will affect a single or multiple biological pathways
• Consecutive cleavage order mapped for diubiquitin-processing DUBs: For DUBs that process diubiquitin through a distal-to-proximal cleavage mechanism, the multiplexed assay captured the temporal order of cleavage events across all eight linkage types simultaneously, revealing that some DUBs (e.g., OTUD2) cleave specific linkages (K11, K48) with a preferred order that is not apparent from end-point measurements — information that is critical for understanding how DUBs edit ubiquitin chains in cells
• 22 DUBs profiled across 4 subfamilies with comprehensive specificity landscapes: The study generated the most comprehensive single-study dataset of DUB linkage selectivity to date, including DUBs for which linkage preferences were previously unknown (USP10 showed K63 selectivity, OTUD1 and OTUD3 showed distinct K11/K48 preferences), and provided the first direct side-by-side comparison of DUB activity across the USP, OTU, UCH, and MJD subfamilies under identical assay conditions — establishing a reference dataset for the DUB research community
• Open-source data analysis pipeline for intact protein MS deconvolution: Mass spectra were deconvoluted using open-source algorithms (UniDec, a universal deconvolution program for native mass spectrometry and ion mobility), and the relative abundance of each diubiquitin linkage was quantified from the deconvoluted zero-charge mass spectra, providing a reproducible and transferable data analysis framework that enables other laboratories to adopt this multiplexed DUB activity profiling approach without proprietary software dependencies

Significance: This landmark study established a new paradigm for DUB activity profiling by demonstrating that neutron-encoded diubiquitin substrates, combined with intact protein LC-MS readout, enable comprehensive, multiplexed assessment of DUB linkage selectivity in a single reaction. The concentration-dependent selectivity finding has direct implications for drug discovery, suggesting that selectivity profiles generated at single (typically high) enzyme concentrations may overestimate the promiscuity of DUB targets and underestimate the potential for developing selective inhibitors. Our service platform directly incorporates this methodological framework — multiplexed intact protein MS-based DUB activity profiling with linkage-specific diubiquitin substrates — as a core component of our biochemical DUB activity assay offering, adapted and optimized for customer-specific DUB targets and inhibitor screening applications.

Adapted from van Tol et al. (2023). Neutron-encoded diubiquitins to profile linkage selectivity of deubiquitinating enzymes. Nature Communications 14:1661. (CC BY 4.0)

Representative Results: DUB and Ubiquitin Enzyme Activity Assay Performance and Data Outputs

Our DUB and ubiquitin enzyme activity assay platform delivers integrated data packages combining biochemical activity measurements, cell-based target engagement, and ubiquitin proteomics for comprehensive functional characterization of ubiquitin enzyme activity in drug discovery programs. The representative data below illustrates typical output quality and performance across our four complementary platforms.

Platform Performance Specifications

Representative data outputs from our DUB and Ubiquitin Enzyme Activity Assay platform. Left: Biochemical Ub-AMC kinetic assay with inhibitor IC₅₀. Center-left: ABPP-LC-MS/MS DUB family selectivity profiling. Center-right: Cell-based target engagement by cR10-Ub-PA probe. Right: K-ε-GG ubiquitin remnant proteomics in degrader-treated cells.

Key data deliverables included in every DUB and ubiquitin enzyme activity assay project:

• Biochemical activity assay data package — Raw fluorescence or AlphaLISA traces, V₀ values, IC₅₀ curves with 95% confidence intervals, Z′-factor quality metrics, and DUB panel selectivity ratios for each tested compound, with raw data files in standard plate-reader format
• ABPP-LC-MS/MS activity profiling data package — Complete list of all detected DUBs with MS/MS identification scores, TMT reporter ion intensities, activity ratios (treated/control) for each DUB at each compound concentration, selectivity heat maps, and raw MS data in mzML format
• Cell-based target engagement data package — Target occupancy percentages for each DUB at each compound concentration, proteome-wide selectivity profiles, pull-down immunoblot images, AlphaLISA dose-response curves, and EC₅₀ values with confidence intervals
• K-ε-GG ubiquitin remnant proteomics data package — Complete list of all identified and quantified ubiquitination sites with localization scores, differential ubiquitination analysis with statistical testing (FDR-corrected p-values), pathway enrichment results, PCA and volcano plots, and heat maps across all experimental groups
• Methods documentation — Complete protocols for enzyme preparations, probe synthesis or sourcing, assay conditions, LC-MS acquisition parameters, and data analysis methods, formatted for publication methods sections and regulatory reference

Related Services

Our DUB and ubiquitin enzyme activity assay platform is part of a comprehensive drug discovery service portfolio spanning activity-based profiling, mass spectrometry-based proteomics, and targeted protein degradation analysis for oncology, neurodegeneration, inflammation, and PROTAC development programs.

• Ubiquitylomics Analysis — Global K-ε-GG ubiquitin remnant LC-MS/MS profiling for comprehensive ubiquitination site identification and quantification in any biological system
• Protein Degrader Ubiquitination Efficacy — Targeted assessment of PROTAC-induced ubiquitination by MS-based ubiquitin remnant quantification and cellular ubiquitination assays
• Modificated Protein Degrader Proteomics — Multi-omics characterization of targeted protein degradation by PROTACs and molecular glues using quantitative proteomics
• AP-MS for Protein Degrader — Affinity purification-mass spectrometry for identifying degrader-induced protein interaction networks and ternary complex components
• PTM Enzyme Activity & Inhibitor Screening — Comprehensive PTM enzyme activity profiling and small-molecule inhibitor screening across kinase, DUB, HDAC, and other PTM enzyme classes
• Kinase Activity Profiling — Activity-based kinase profiling and inhibitor selectivity screening using multiplexed MS-based and biochemical assay platforms
• HDAC/HAT Activity Assays — Biochemical and cell-based activity assays for histone deacetylase and acetyltransferase characterization and inhibitor screening
• Ubiquitinated Peptide Enrichment — Immunoaffinity enrichment of ubiquitinated peptides (K-ε-GG, K-ε-LRGG) for comprehensive ubiquitination site mapping by LC-MS/MS

FAQs

References

1. van Tol BDM, et al. Neutron-encoded diubiquitins to profile linkage selectivity of deubiquitinating enzymes. Nature Communications. 2023;14:1661.
2. Barroso-Gomila O, et al. BioE3 identifies specific substrates of ubiquitin E3 ligases. Nature Communications. 2023;14:1556.
3. Liu Y, Yang J, Wang T, et al. Expanding PROTACtable genome universe of E3 ligases. Nature Communications. 2023;14:6509.

For research use only. Not for use in diagnostic procedures.